Document is current

Article History

Received: 7 October 2021

Accepted: 10 December 2021

First Online: 23 January 2022

Declarations

:

: David H. Ilson has received research funding from and served on advisory boards for Astellas, Eli Lilly, Pieris, and Taiho, and served on advisory boards for AstraZeneca, Amgen, Bayer, Bristol-Myers Squibb, and Roche. Yelena Y. Janjigian has received research funding provided to the institution from Rgenix, Boehringer Ingelheim, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly, and Merck, served on advisory boards for Rgenix, Merck Serono, Bristol-Myers Squibb, Eli Lilly, Pfizer, Bayer, Imugene, Merck, Daiichi-Sankyo, Zymeworks, Basilea Pharmaceutica and AstraZeneca and holds stock options for Rgenix. Geoffrey Y. Ku has received honoraria and research funding from Merck, Bristol-Myers Squibb, and Pieris, and research funding from AstraZeneca, Zymeworks, and Daiichi Sankyo. All remaining authors have declared no conflict of interest.

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.

: Informed consent was obtained from all patients in this study.

: All authors and the sponsor of the study gave consent to publication of this study.

: The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

: Not applicable.